DTaP acellular pertussis vaccine data

NVX (Beltsville, Md.) announced that Phase III data on its DTaP acellular pertussis vaccine showed efficacy and reduction in severity of disease in those who did get sick despite the vaccine in the Danish trial.

As reported by the Swedish investigators at the meeting of the American Society of Microbiology in Washington, the median duration in days of whooping cough and vomiting was zero in the vaccinated group, and at least 20 days in the control group that received a diphtheria-tetanus (DT) vaccine. ...